Lawsuit, Warning Letter Mark Return Of B. Cepacia As GMP Issue
Executive Summary
Lawsuit over infant's death and warning letter over recurring contamination underscore the importance of screening for Burkholderia cepacia and when found, removing the microorganism from pharmaceutical manufacturing processes.
You may also be interested in...
The Quality Lowdown: Enforcement And Compliance During A Lingering Pandemic
US FDA oversees plants straining to meet demand for COVID-19 vaccines and treatments, while cracking down on adulterated hand sanitizers.
FDA Offers Sage Advice On Contract Manufacturers: Don't Mix Drugs And Car Wax
How could Sage Products have known that its contract manufacturer, ChemRite, was making Sage's oral solutions on the same equipment as toxic car wax? FDA's Thomas Cosgrove says the key is a strong quality agreement.
FDA Enforcement And Compliance In Brief
FDA traces B. cepacia to PharmaTech, Nippon Workers blocked FDA investigator, Yangzhou Hengyuan used wrong API, FDA bans two Chinese firms, and Kaley to provide FDA data integrity training.